Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP-102 +/- Trametinib in Advanced BRAF V600+ Solid Tumors
NCT05275374Phase 2Not yet recruiting
- Sponsor
- Xynomic Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of XP-102 in melanoma, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by Xynomic Pharmaceuticals. Primary endpoints: Safety of XP-102 at 28 days, Pharmacokinetics of XP-102 at 28 days and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
XP-102
03
Conditions
melanomacolorectal cancer (CRC)non-small cell lung cancer (NSCLC)thyroid cancer
Beyond the preview
Go deeper on NCT05275374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275374.